Advertisement

AI Bias Analysis

4 models · Takes ~15 seconds

MedPage Today

Avapritinib's Effect Durable in Indolent Systemic Mastocytosis

HealthDaily Composite

(MedPage Today) -- Long-term data from the PIONEER trial, presented at the American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting, support the durability of response with the KIT inhibitor avapritinib (Ayvakit) for indolent...

M

Source

MedPage Today

Read full article at MedPage Today

Opens original article in a new tab

Advertisement

Related Health Stories

Advertisement